Genzyme sees Ceredase/Cerezyme sales of $250 mil. in 1996; plant approval will allow more growth.
Executive Summary
GENZYME CEREZYME MANUFACTURING FACILITY WILL ALLOW GROWTH BEYOND $250 MIL. in sales for the company's Ceredase/ Cerezyme Gaucher's disease treatment products, Genzyme CEO Henri Termeer told the Alex. Brown conference in Baltimore. Genzyme expects sales of the alglucerase products, predominantly from placenta-derived Ceredase, to reach $250 mil. this year, Termeer said. The firm's Boston manufacturing facility for recombinant Cerezyme is "in the final phases of review by FDA," Termeer added.